Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
May 7, 2026
Earnings Call Speaker Segments
Larry Keusch
executiveHello, everyone, and thanks for joining us on the Teleflex Inc. First Quarter 2026 Earnings Conference Call this morning. You can find the press release and the slides that go with this call on our website, teleflex.com. Just a note that a replay is going to be posted on our website; if you'd like to listen to it, the details are in our press release from this morning. On the line with us today are Stuart Randle, our Interim President and Chief Executive Officer, and John Deren, our Executive Vice President and Chief Financial Officer. Stu and John are going to give prepared remarks, and after that, we'll take your questions in the Q&A session. Before we get started, I want to point out that certain matters we'll talk about on this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. We want to caution you that these statements are indeed forward-looking in nature and are subject to risks and uncertainties, so actual events or results could differ materially. The factors that might cause actual results or events to differ materially include, but aren't limited to, the factors mentioned in our press release today and in our filings with the SEC, including our Form 10-K, which you can access on our website. With that, I'll hand the call over to Stu for his remarks.
Stuart Randle
executiveThanks, Larry, and good morning to all of you. Ahead of walking through our first quarter 2026 results, I want to share an update on where we stand with our strategic objectives and our dedication to maximizing long-term shareholder value. At Teleflex, we've shown tangible progress in refining our portfolio and positioning the company to capture the significant opportunities in front of us. Back in July 2025, we closed on our purchase of BIOTRONIK's Vascular Intervention business, which broadened our coronary intervention offerings and gave us a worldwide presence in the rapidly expanding peripheral intervention market. Then in December 2025, we announced deals to divest the acute care, interventional urology, and OEM businesses as part of our broader transformation plan, which will create a more concentrated medical technologies leader with a stronger forward revenue CAGR, more exposure to core critical care and high-acuity hospital markets, and a tighter portfolio spanning Vascular Access, Interventional, and Surgical; these strategic divestitures are still expected to close in the second half of 2026. Regarding OEM, we hit a key milestone in March when the Hart-Scott-Rodino waiting period lapsed; we're now concentrating on satisfying the remaining closing conditions, with a goal of closing in the third quarter of 2026. On a separate note, in March, both Teleflex and the purchaser of the acute care and interventional urology businesses received a second request for additional information from the U.S. Federal Trade Commission. We're working cooperatively with the FTC and still anticipate that transaction will close in the second half of 2026. Our commitment stands to deploy the proceeds from these divestitures toward a share repurchase program of up to $1 billion and to pay down debt by $800 million, which mirrors our disciplined approach to capital allocation and our emphasis on boosting shareholder value and financial flexibility. We now expect to kick off opportunistic share repurchases in the open market during the second quarter of this year, earlier than the previously anticipated timing of after the strategic divestitures are completed. This move demonstrates our confidence in the business's value, the headway we're making on our transformation plan, and our dedication to disciplined capital allocation and long-term shareholder value creation. Teleflex is also advancing on its strategic priorities, which include delivering durable performance and establishing a clear financial profile through better margins, reduced interest expense, and stronger adjusted earnings per share over time. During the first quarter, we either met or surpassed our internal expectations for revenues, margins, and adjusted EPS. Pro forma adjusted constant currency growth rose 5.1%, while adjusted operating margin came in at 18.1%. We're staying focused on completing the sale transactions and hitting our financial targets for 2026, along with generating additional momentum to drive sustainable growth and operating leverage. As we previously announced, we kicked off a multiyear restructuring plan that's projected to deliver roughly $50 million in annual pretax cost savings once it wraps up in mid-2028. Restructuring activities, which remain on track, got underway in the first quarter of 2026, and savings should pick up speed in the second half of the year. Back in April, Teleflex made an announcement about governance changes. Those included putting forward Michael J. Tokich — who previously held the roles of Senior Vice President and Chief Financial Officer at STERIS — for nomination to the Board of Directors, along with the intention to form a new growth and operating committee within the Board. What these steps show is that we remain focused on solid governance, careful oversight and performance over the long term. We also let it be known that both Dr. Stephen Klasko and John Heinmiller will wrap up their current terms on the Board when we hold our next Annual Stockholders Meeting. Dr. Klasko has just taken on a major new leadership position in health care, while Mr. Heinmiller is off pursuing other professional interests. Speaking for the Board, I'd like to express our gratitude to Steve and John for all they have meaningfully contributed and for the dedication they showed Teleflex across their numerous years of service, and we wish each of them the very best going forward. Once the annual meeting concludes, Andrew Krakauer, who right now holds the position of Chair of the Board's Comp Committee, is set to take over from Steve as Chair of the Board. Andy has been a Director of Teleflex going back to 2018. From 2009 until 2016, he was CEO and a Board member at Cantel Medical Corporation, which throughout his time there was an NYSE-listed company providing infection control products and services. When you put all of this together, these moves point to a more concentrated portfolio, better governance, capital allocation that is disciplined and an obvious route toward creating value. And in our view, they put Teleflex in a position to achieve better execution and improved long-term performance. Last of all, I'd like to extend a welcome to Jason Weidman, who becomes Teleflex's next President and CEO starting June 8. Jason has clearly proven himself as a medical technology leader, bringing over 25 years of experience in the industry along with a robust history of building and scaling businesses on a global scale. His extensive expertise in medical technology and his demonstrated ability to drive growth, innovation and operational execution mean he is a great fit to guide Teleflex into its next chapter and to help speed up the opportunities that lie ahead. Serving as Interim President and CEO of Teleflex has been an honor, and I'm eager to keep supporting the company in my capacity as a Board member. Now I'll turn to our first quarter continuing operations results and the revised financial guidance for 2026. Every growth rate I mention is on a year-over-year pro forma adjusted constant currency basis, unless I say otherwise. Pro forma adjusted constant currency growth for 2026 leaves out the effect of foreign exchange, the Italian payback measure of $9 million in the second half of 2025 and the impact of roughly $14 million in continuing operations product revenue that was discontinued at the close of 2025 as a result of a strategic realignment, though it does factor in revenue produced by the acquired Vascular Intervention business for the prior full year period. All of my remarks concern the continuing operations for the first quarter of 2026. During that first quarter, Teleflex revenues came to $548.3 million, which is up 32.3% year-over-year on a GAAP basis and represents a rise of 5.1% on a pro forma adjusted constant currency basis. During the quarter, we showed solid execution and, to a smaller degree, also gained from certain order timing within our surgical instrument portfolio. Adjusted earnings per share for the first quarter came in at $1.39, which represents a 3.5% decline compared with the prior year. Near the start of the second quarter, we received notice that a pair of third-party product suppliers had begun a recall covering certain components contained in some of our vascular and interventional kits. We have pinpointed steps to bring our products back to market, and a remediation program is now in progress. Within our first quarter results, we have set aside the required estimated cost provision to remediate our existing product stock. While the remediation steps could lead to somewhat elevated back orders as the second quarter ends, at present we do not expect a material effect on our full year 2026 revenue guidance, since we remain focused on meeting our customers' needs. Let's now take a closer look at how our first quarter revenue performed. I'll start by walking through our revenues by global product category for the first quarter. Beginning with Vascular, revenue rose 4.8% versus the prior year to $236.8 million, mainly fueled by growth in our hemostatic products within our central venous and other access portfolio. Turning to Interventional. Revenue reached $204.7 million, up 3%. Results for the quarter were propelled by intraosseous, right heart catheters and complex catheters. We are still integrating the Vascular Intervention business, which closed early in the third quarter of 2025. During the first quarter, the sales forces of the legacy Teleflex Interventional and Vascular Intervention businesses were brought together. As anticipated, we have seen some disruption stemming from the integration and restructuring activities, yet we still expect momentum to improve in the second half of the year, supported by our larger presence and cross-selling opportunities in the cath lab. Consistent with our commitment to boost R&D investment for innovative new technologies, we keep advancing our clinical study for the Freesolve drug-eluting resorbable magnesium scaffold technology. Freesolve's pairing of temporary scaffolding with drug delivery is expected to address the present trend in interventional cardiology and endovascular procedures toward leaving nothing behind. Enrollment for the BIOMAG-II study, a European pivotal trial for Freesolve, keeps surpassing our assumption for the study, putting us on track for a late 2027 data readout; we plan to broaden our regulatory pathway for Freesolve into additional geographies, including launching the BIOMAG-III pivotal trial in the U.S. during 2026. In our Surgical business, revenue totaled $106.8 million, up 9.9%, chiefly driven by strong performance in our ligation clip along with some order timing in our instrument portfolio. Instrument orders can be uneven from quarter to quarter, and we expect growth to moderate somewhat in the second quarter. That wraps up my remarks on the first quarter revenue performance. Now I'd like to hand the call over to John for a more detailed review of our financial results. John?
John Deren
executiveAppreciate that, Stu, and good morning to everyone. Every figure I'll reference is presented on a continuing operations basis for 2026. Because of the reclassification into discontinued operations, the historical continuing operations numbers carry the effect of stranded costs across all periods shown. Since Stu already walked through revenue, I'll start with margins. Adjusted gross margin for the first quarter of 2026 came in at 61.4%. That 470 basis point drop from a year ago was driven mainly by the unfavorable effect of tariffs, quality remediation charges tied largely to the third-party supplier disruption Stu brought up earlier, greater logistics and distribution expenses, plus the addition of the Vascular Intervention acquisition, whose gross margin sits slightly below the corporate average. Adjusted operating margin for the first quarter of 2026 landed at 18.1%, and the 510 basis point decline mirrored the year-over-year gross margin pressure, greater operating expenses tied to acquiring the Vascular Intervention business, and stepped-up R&D investment, partly offset by favorable foreign exchange rates. Adjusted net interest expense came to $24 million in the first quarter, versus $17 million in the same period a year earlier. That year-over-year rise stems mostly from borrowings taken on to fund the Vascular Intervention acquisition. Our adjusted tax rate for the first quarter of 2026 stands at 18.3%, compared with 16.4% a year ago. The increase from last year is largely attributable to greater tax expense related to stock-based compensation. Moving to the bottom line, adjusted earnings per share for the first quarter was $1.39, a decline of 3.5% year-over-year. That decrease is mainly the result of tariffs and higher interest expense, partly offset by greater revenue and adjusted operating income, including the effect of the Vascular Intervention acquisition, along with increased R&D spending and a reduced share count. As of the close of the first quarter, our balance of cash equivalents and restricted cash equivalents stood at $329.6 million, down from $402.7 million at the end of 2025. Net leverage at quarter end was roughly 2.5x. Now I'll move to our financial guidance. As we've said before, 2026 results contain several transient factors stemming from our strategic divestitures that will weigh on near-term performance, and we expect to offset these once both transactions close. So we believe 2027 will better reflect the underlying business going forward, ultimately establishing a clear financial profile with meaningful gains in margins, interest expense, and adjusted earnings per share. With that framing, let me walk through the items affecting our 2026 results. First, our 2026 guidance incorporates the fully burdened cost structure for RemainCo, including roughly $90 million of stranded costs, while excluding any favorable effects from the TSA or MSAs. Second, precisely when the strategic divestitures close will dictate how quickly we can deploy capital in 2026. As a reminder, we anticipate net proceeds of about $1.8 billion after tax from the divestitures. Our dedication to giving back a substantial amount of capital to shareholders hasn't changed — that's through the $1 billion share repurchase authorization we announced earlier, plus our plan to pay down $800 million of debt using what's left from the strategic divestitures. As we've said before, we expect to kick off opportunistic buybacks in the open market under that existing $1 billion authorization sometime in the second quarter. Whether we actually do those repurchases depends on market conditions at the time and what the company needs for operating cash flow. Looking ahead to 2027 and past that, we believe these capital deployment moves, together with the effects of the TSA and MSA arrangements and our work to further mitigate stranded costs and rightsize the organization, will drive a substantial rise in our operating income and margins, and in our adjusted EPS as well. Now an update on the 2026 guidance. Keep in mind this guidance is on a continuing operations basis, leaving out acute care, interventional urology and OEM; for 2026 we still expect pro forma adjusted constant currency revenue growth between 4.5% and 5.5%. On adjusted earnings per share, we still expect a range of $6.25 to $6.55 for 2026. The guidance doesn't factor in the expected positive effect of our announced plans to repurchase $1 billion of our common stock and repay debt, which will be funded mainly by proceeds from the strategic divestitures. We expect those moves to produce a meaningfully lower share count and significantly reduced interest expense in 2027 and beyond. Even though we haven't baked the benefits of these actions into our 2026 adjusted EPS guidance, we still anticipate completing the strategic divestitures in the second half of 2026, with the OEM transaction expected to close in the third quarter. All told, we expect these factors to drive significantly higher adjusted EPS starting in 2027. Also, for modeling purposes, here's what you should consider: the foreign exchange impact for 2026 is still expected to be roughly $14 million. We continue to expect our 2026 adjusted operating margin to be approximately 19%, which reflects the full impact of approximately $90 million in stranded costs tied to the separation activities and no offsetting benefit from the TSA and MSA arrangements during 2026. I'd also point out that our 2026 operating margin includes R&D investment of approximately 8% of sales. Notably, when you factor in the positive effects of the TSA and MSA arrangements in terms of lowering the operating expense profile for continuing operations, we estimate our underlying steady-state adjusted operating margin will be approximately 23%, which is 400 bps above our fully burdened adjusted operating margin guidance for 2026. Going forward, we see opportunities over the next several years to improve adjusted operating margin through operating leverage from revenue growth and other cost savings initiatives above our steady-state operating margin profile of approximately 23%. Now moving to assumptions below the line. For the whole of 2026, we anticipate net interest expense will come in at roughly $105 million. This projection takes into account the refinancing of the $500 million in 4.625% senior notes that mature in November 2027, and it doesn't factor in any reduction of debt tied to the after-tax proceeds from the strategic divestitures. And lastly, our expectation for the tax rate in 2026 remains right around 13.5%. That wraps up what I had prepared to say. At this point, I'd like to hand things back over to Stu for some closing commentary.
Stuart Randle
executiveThank you, John. To wrap up, I want to emphasize 3 main points from Q1 of 2026. To begin, Teleflex is undergoing a transformation aimed at refining our portfolio, building a more concentrated medical technologies leader, and setting up our company for significant opportunities to create value moving forward. On the pillars of our strategic plan, we keep advancing, and those are anticipated to spark a robust financial profile starting in 2027. Next, we're happy with how Q1 turned out, posting pro forma adjusted constant currency revenue growth of 5.1% compared to a year earlier, which keeps us on pace with our 2026 pro forma constant currency growth guidance range of 4.5% to 5.5%; on top of that, Q1 results line up with our mid-single-digit growth aspirations and strongly demonstrate the sustainable growth potential of our go-forward business. And third, we still anticipate that our 2 strategic divestitures will be completed during the second half of 2026. We stay dedicated to giving back substantial capital to shareholders via our $1 billion share repurchase program, while simultaneously paying down debt to boost our financial flexibility and back future growth and value creation. We're also keeping our attention on ways to offset stranded costs from the separation, starting with recognition of transition service and manufacturing service fees totaling no less than $90 million annualized, and over a longer horizon, through cost optimization. Restructuring has already been kicked off to generate roughly $50 million in after-tax savings, and we're actively evaluating further cost reduction programs. With a leaner portfolio and well-defined strategic priorities, we'll be positioned strongly to deliver sustainable performance and long-term value for shareholders. We anticipate our financial performance will strengthen throughout 2026 and that we'll more completely realize the advantages of our efforts in 2027 and beyond, with substantial gains in adjusted earnings per share. That wraps up my prepared remarks. At this point, I'd like to hand the call back to the operator for Q&A.
Mike Matson
analystI'd like to ask about what you expect for revenue growth in the second quarter. I realize guidance isn't being provided, but a few items in the prepared remarks appear to suggest growth might come in somewhat below the annual rate — the recall matter, the timing of instrument orders, and the interventional sales integration. So I'm not sure what you're willing or able to share on that, but does roughly $567 million, the consensus estimate, feel comfortable to you?
John Deren
executiveSo Mike, yes, regarding your first point, quarterly revenue guidance isn't something we're providing. That said, yes, those observations of yours are — we did state that we'd expect faster growth during the back half of 2026. That view hasn't changed; faster growth is what we anticipate. So you can begin running the numbers down through the P&L. Yes, we have those 2 recalls, which might tie to certain back orders, though for us it's truly a bump in the road. For one of them, product is already flowing in the case of the bigger one, and honestly, the other is quite small. So my thinking is that although risk always exists at some level and there will be puts and takes, for the whole year I don't believe those will cause us problems. Yes, and for Surgical we did observe some instrument order timing. How that unfolds across the year is something we'll keep watching. So telling you precisely that this will be an adjustment landing in Q3 is difficult, though Q2 is possible too; but once again, Q2 revenues aren't being guided by us, and that's everything I can share on that.
Mike Matson
analystAlright, got it. Then regarding the interventional sales integration that got underway during Q1, how much of the disruption stems from cutting head count as opposed to simply redrawing territories? Or does it come from both of those factors combined?
John Deren
executiveWell, there's — would you like to...
Stuart Randle
executiveStu here, and I'll address that. What you raised in your second point is really the main factor — the way we reorganized territories. Once the two sales teams were brought together, we had to realign territories, and that's what's mostly driving the disruption.
Jayson Bedford
analystThis might be a bit of a stale question, but in the first quarter you came in roughly $0.17 ahead of consensus estimates. The annual guidance hasn't moved at all. I realize many variables play into setting guidance. Still, does the EPS guidance take into account any fresh costs you're observing in the business?
John Deren
executiveNo. I'd say, Jayson, we're only a short way into the year. Once again, plenty of pluses and minuses across the quarters. We're quite pleased with how Q1 went. So we've made the call that, for the time being, we'll keep our full-year guidance as is. Once we get further into the second quarter, we'll have a clearer picture, and at that point we can make updates if it makes sense.
Jayson Bedford
analystAll right. Perhaps regarding the top line, expansion was pretty even among those three segments. Surgical clearly stands out as the exception. My assumption is that comps played a role; and clearly, on the Surgical side there were some pluses and minuses. Yet inside that 4.5% to 5.5% growth guidance, could you simply tell us which segments trail, which segments fuel the growth? And then perhaps discuss a few of the segment drivers.
John Deren
executiveYes. So look, I mean, I think we're pleased with every one of the segments. In Vascular, CVCs and hemostatics performed very well. Surgical, it's really about our Hem-o-lok and the instrument orders, as we noted. Interventional is performing very well with complex catheters, drug — DCBs too. So I think we're really pleased with what we're seeing throughout the portfolio. Again, we don't guide by product portfolio. So I'm not going to get too into that. Over the long term, we do see Interventional becoming the bigger grower. I can't — I won't signal that yet for 2026, but I think that is our expectation. We're putting a lot behind the Interventional product space; we're spending most of our R&D dollars there, and we think there's the opportunity for the most innovation there as well.
Matt Taylor
analystWhen it comes to what you anticipate for expenses this year, could you perhaps assist us in framing the inputs — such as how cost inflation is affecting manufacturing and freight? Could you also help us grasp whether there's any margin headwind you're currently observing, or anything you anticipate within the guidance for the year?
John Deren
executiveHonestly, there's nothing major; clearly, we've witnessed a rise in L&D costs as the Iran conflict continues; many contracts were locked in when it began; so that kept our L&D costs lower early in the year. As we reached the quarter's end, we've begun to see that inflation, and we believe we have numerous chances to offset it. Thus, we currently have several ongoing improvement process programs actively in place to counter that. So at this moment, we believe the risks we observe fall inside the guidance range we've provided on operating margins.
Ravi Misra
analystI'll get both my question and my follow-up out right away. To start, could you share a bit more about what the new Board committee you announced is actually meant to do? How operations growth fits in, and how it will be put together in terms of membership? Then, regarding Freesolve, you seemed to mention that enrollment in Europe moved along more quickly than anticipated; for BIOMAG-III in 2026, could you help set expectations around how long completion might take given what you've learned, and perhaps when a readout could come if all goes smoothly?
Stuart Randle
executiveStu here. I'll handle the growth and operating committee; next week we have a Board meeting, and at that point we'll lay out the framework for the committee along with its members. It's reasonable to say the emphasis will be narrower — or somewhat more granular — on how the company runs, and in particular on the way our growth plans get established and how we track whether those plans are being carried out.
Larry Keusch
executiveOkay, Ravi — Larry here. I want to touch on the BIOMAG studies. Right, with BIOMAG-II over in Europe, our patient enrollment has actually been running ahead of the timeline we'd projected, and we're getting close to finishing up that enrollment phase. Once we've got it all closed out, we'll of course make that known to everybody. The design calls for a 12-month follow-up period after the final patient is brought in. That ought to give you a sense of when this trial will reach its conclusion, and after that, clearly, comes the data analysis. Our expectation remains that those results will be reported during 2027, in the later part of that year. As for the U.S., just as we've said before, BIOMAG-III is going to kick off in 2026. Its study protocol closely mirrors that of BIOMAG-II. So figure on patient numbers that are comparable. How enrollment unfolds remains to be seen. Results can vary from one region to another. Still, my expectation is that we'll likely see those data reported at some point around 2030.
Shagun Singh Chadha
analystSo my understanding is that Jason's first day will be June 8. Before he comes aboard, could you explain what made him the ideal candidate for this company? And after he steps into the position, when should we anticipate learning about the strategic direction of the company? Also, is an Investor Day being planned? Then I have one brief follow-up.
Stuart Randle
executiveAbsolutely. I appreciate the question. We're really thrilled that Jason is joining us. Like we mentioned, his start date is the 8th. Before that, he has certain commitments with Medtronic, though he will definitely be engaged with our company before his official first day. What led us to choose him? There were essentially 3 or 4 factors. To begin with, a match with our culture and values, which center on ethics, integrity, and accountability. Next, we were looking for a leader with a demonstrated record of growth. Jason certainly showed that kind of growth while running the stent portfolio at Medtronic. Third, we needed somebody capable of navigating substantial complexity. As you're aware, we're bringing BIOTRONIK together and pursuing sales of our businesses. And obviously, a person who has worked at Medtronic — which, as you know, is an enormous, extremely complex, matrix-style organization — has enjoyed a highly successful career there. So he has clearly witnessed and dealt with that complexity. And finally, a worldwide viewpoint. Throughout his career, he has run a very extensive product portfolio across the globe. Those are roughly the main reasons we selected him. I speak with him nearly daily. He can't wait to begin, and we're eager to have him with us. As for an Investor Day, nothing is scheduled right now. We will definitely let you know once Jason has come aboard and grown familiar with the organization. It's a topic we've discussed, and we will arrange something at some point down the road.
Shagun Singh Chadha
analystGreat. Then, as a quick follow-up, I believe during the previous quarter you gave us some directional perspective regarding 2027. I wanted to ask if you might address that. When it comes to sales, with the midpoint being 5% growth, would that serve as a solid base case moving forward? Then regarding operating margins, I believe excluding stranded costs, you pointed to the mid-20s, and you also mentioned in your remarks today that for this year, there's roughly a 400 basis point impact on the burdened operating margin. So any directional perspective would be useful.
John Deren
executiveYes, Shagun, we didn't give any guidance for 2027. What we did give, though, as you mentioned, regarding a normalized operating margin was closer to that 23% level once stranded costs are factored in. And we believe there's substantial opportunity to exceed that as we keep growing and gain additional leverage from the P&L moving forward. But that's really the only item we guided to in — for 2027. Clearly, we've provided you the components to consider concerning buyback and interest expense and the benefits we'll see in 2027, so — for your own models. But yes, when it comes to top line, we're not ready to begin guiding top line until we're a bit further into 2026.
Matthew O'Brien
analystTo begin with, perhaps on a broader level, there was chatter regarding some possible interest in Teleflex, whether strategic or from a private equity standpoint, and I'm not certain what you're able to discuss, but I did hear that, observing two Board members who aren't standing for reelection. So I'm simply curious whether the company received an approach about a deal, you evaluated it as a Board and determined, no, this isn't something we're interested in, and therefore the hiring of Jason, or are those two paths or factors entirely separate from one another? And then I have one more question.
Stuart Randle
executiveYes. This is Stu. We don't provide any commentary on market rumors and speculation. We addressed these matters in our March 27 press release. So I'll simply point you there for whatever we've said.
Matthew O'Brien
analystAll right, that's reasonable. And now perhaps something for John. I realize that figuring out the precise schedule for buybacks isn't straightforward. But here's the thing — it's a substantial figure, $1 billion in repurchases — do we believe that could be wrapped up before this calendar year ends? Or is your expectation that it stretches into '27?
John Deren
executiveWell, considering how large it is — first, just to remind everyone, we'll begin making some open market purchases in Q2, based on the current stock price. We believe there's a chance to do that. Naturally, that comes before the proceeds. So there's no promise about how much we'll repurchase during the second quarter, at least not until we can complete the initial sale — which we anticipate will be the OEM transaction. However, because the buyback is so sizable, it's quite possible those purchases will extend into 2027. So if we simply consider how the two sales will probably unfold, and if you looked only at the money coming in from the sales, you'd probably still be buying into the first quarter of 2027, simply because of the volume limits we'd face.
Analyst
analystTo begin with, out of that $90 million in stranded costs, what portion has already come through in the first quarter? Also, does the quarterly pattern run evenly, or is it weighted toward the back half?
John Deren
executiveI'm sorry. Could you repeat the second part of your question?
Analyst
analystRegarding how the remaining stranded costs will be timed, is a straight-line pace what we should anticipate? Or do they lean toward the second half?
John Deren
executiveA straight-line pace is the right way to look at it. Stranded costs, you know, there isn't much of a precise method behind them. It's an idea, correct? These are overhead expenses we continue to carry for the whole of Teleflex that we expect we can — we think we can completely offset once the company is separated. By the time you reach 2027, or even the latter portion — the tail end of this year, after the TSAs and MSAs are established, they will fully cover the stranded costs. After that, it comes down to how those restructuring programs address them on a permanent basis. So you can figure that stranded costs will stick around for probably most of this year, up until the fourth quarter, when the TSAs and MSAs kick in. And for 2027 they won't pose a problem, and after that we must keep working to ensure they don't turn into a problem beyond 2027, into 2028; so — but right now they're reflected in the figures, and they're also in the comparison figures, so to speak, given that we've restated everything for 2025.
Analyst
analystAlright. Just to confirm that $90 million figure — and how much of it landed in Q1?
John Deren
executiveSorry, could you repeat that?
Analyst
analystJust to confirm what you're guiding to — the $90 million in stranded costs — and then what amount actually came through in the first quarter?
John Deren
executiveWell, once more, these items are conceptual in nature. They sit inside your overhead, your corporate overhead, that sort of thing. So in that regard they aren't a specifically pinpointed cost, correct? So I suppose I'd suggest viewing them on a ratable basis, right, as the year unfolds.
Mike Polark
analystI want to ask a follow-up about Interventional, which posted 3% pro forma constant currency growth for the quarter. That falls short of the mid-single digits plus target. I picked up on a few puts and takes. What I am trying to get at is why this particular quarter came in a bit under target growth. Does that trace back to disruption from integrating the sales force? Does it trace back to the recall involving a third-party supplier? Or is there another factor you would want us to weigh?
John Deren
executiveNo. Here is how it looks — for Interventional specifically, our expectation was that the first half of the year would be slower than the back half, and there are two reasons for that. First, we carried out a major restructuring. At the end of Q4, we announced a major restructuring tied to the VI acquisition; that begins happening, obviously, in Q1; so those actions were underway, along with some of the disruption Stu has already brought up. Those are really the items I can discuss; we see them as transient in the Q1 going into the Q2 a little, and after we sort of work through that transition, we expect the back half of the year to recover nicely.
Mike Polark
analystRegarding Surgical, that upside growth this quarter and when instrument orders landed — I picked that up clearly. Are new products being introduced in that area? Would you call it share gain? Or is it purely a timing matter? Also, on that second point, do those orders for the bariatric stapler get counted in what you said? If they don't, I'd like an update on how that product is doing, considering the market channel.
John Deren
executiveSurgical performed extremely strongly, and my view is that strength will carry forward; performance was solid throughout our product portfolio. Hem-o-lok performed strongly. The bariatric stapler performed strongly. Its base is far smaller. Instrument orders have performed strongly all year long. That is definitely — that is genuinely the sole timing matter this quarter. Aside from that, Surgical's results were truly robust. So we have been — the quarter leaves us quite pleased, and we anticipate some good opportunities ahead as the year unfolds.
Brad Bowers
analystI'm filling in for Anthony. There are possibly two parts to this. I just wanted to dig deeper into Interventional. Clearly, the modeling is somewhat uneven, yet that was the single area that came in slightly under what we had modeled, though naturally, the ramp-up is anticipated; therefore, I was hoping to learn about visibility regarding the integration and what your expectations are for how that ramps and finishes 2027. And then, I admit this is somewhat nitpicky, but I'd like to hear about a new CEO arriving, with experience in complicated businesses, yet the latest Teleflex deals are aimed at making you folks leaner; so I wanted to learn about the positives and negatives. Naturally, the abilities carry over, but I just wanted to get a sense of the mentality and the continuing Teleflex going forward.
John Deren
executiveAll right. Well, I'll have Stu address the CEO remark. But I believe ultimately, this aligns with what I've stated before, during the initial six months of the year, we anticipated somewhat reduced growth owing to the transition and the restructurings we discussed. And once more, we anticipate faster growth during the latter half of the year. That's the most I can offer. Again, we aren't providing quarterly guidance, and we aren't providing guidance by business. Having said that, I'll have Stu respond to the remaining question.
Stuart Randle
executiveAbsolutely. With Jason joining us, I want to say again how thrilled we are to have him. Something I didn’t mention before: what really appeals to us is how wide-ranging his background is from his time at Medtronic, covering both the cath lab and the peripheral business. That means he brings experience with stents, drug-coated balloons, coronary catheters, and peripheral catheters. So that product knowledge is something we value, and the growth he showed at Medtronic across all those roles gives us a lot of confidence that he’ll help us push for faster growth going forward.
Travis Steed
analystAt a broader level, I'm just wondering how you weigh exploring every possible route to generating shareholder value, along with balanced returns for shareholders adjusted for risk, against sticking with your longer-range strategic plan. I'd really like to hear your big-picture thinking on that.
Stuart Randle
executiveYeah. It's Stu here — I think once more I'll point back to what we've already said in public, especially about the fact that we've stated openly that any genuine acquisition offer will get thorough, careful consideration. We're examining every avenue for creating value over the long term and how we can best deliver it. So the Board remains open, is reviewing things, and has taken a very thoughtful approach in doing so.
Travis Steed
analystOkay, that makes sense. And regarding tariffs, what have you factored in for them within the guidance? And should refunds come through, would that represent additional upside to what you've projected?
John Deren
executiveCorrect — any refunds we receive would add upside to the guidance. My sense is we're positioned similarly to most others in the market, operating under what I'd describe as a contingent gain approach. Essentially, we're waiting for the tariff itself to come through — or at least to receive confirmation that we'll recover those tariffs once we file for them. So upside certainly exists there. At present, roughly $33 million related to tariffs sits within our full year guidance. So those refunds would clearly provide some additional upside. Bear in mind, a portion of those refunds would fall in — relating to 2025, what we've already paid; and since that amount gets capitalized and carried forward into 2026, you'd see a distinct benefit during 2026 across the first 2 quarters.
Larry Keusch
executiveAppreciate that, Priva, and thanks to all of you for being with us on today's call. That brings the Teleflex Inc. First Quarter 2026 Earnings Conference Call to a close.
Operator
operatorYou may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.